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Thrombospondin-1 (TSP-1), a multifunctional matricellular glycoprotein, can activate trans-
forming growth factor-b, an important profibrotic cytokine involved in various fibrotic
diseases. TSP-1 is expressed in the lung tissue of animal models of bleomycin-induced pulmo-
nary fibrosis and in patients with some interstitial lung diseases. The present study investi-
gated the serum and bronchoalveolar lavage fluid (BALF) levels of TSP-1 in the idiopathic
interstitial pneumonias (IIPs) and the relationship between these levels and other clinical
factors. The TSP-1 in the serum and BALF were measured in 45 patients with pathologically
diagnosed IIPs [22 with usual interstitial pneumonia (UIP), 23 patients with non-specific inter-
stitial pneumonia (NSIP)], as well as in 28 patients with pulmonary sarcoidosis and 15 healthy
volunteers using a competitive enzyme immunoassay. The expression and localization of TSP-1
in the lungs were analyzed by immunohistochemical staining. The serum TSP-1 levels were sig-
nificantly higher in patients with IIPs than in either those with sarcoidosis or the controls.
These levels correlated well with those of an angiogenic cytokine vascular endothelial growth
factor while correlating inversely with the %VC. Positive immunostaining of TSP-1 was predom-
inantly observed in the regenerated alveolar epithelium and alveolar macrophages in the lung.
Our findings suggest that the circulating TSP-1 levels are associated with the presence of inter-
stitial pneumonia, but further studies are required before we can definitively conclude that
TSP-1 plays a role in the pathogenesis of these diseases.
ª 2008 Elsevier Ltd. All rights reserved.nt of Respiratory Medicine,
, Yufu-city, Oita 879-5593,
1 97 549 4245.
.ac.jp (H. Ishii).
8 Elsevier Ltd. All rights reservedIntroduction
Emerging evidence supports a major role for a thrombo-
spondin-1 (TSP-1) and transforming growth factor-b (TGF-b)
axis in fibrotic disease. TGF-b is a potent and tightly.
1626 M. Ide et al.regulated cytokine known to affect growth, differentiation,
and gene expression.1 An excessive amount of active TGF-b
causes enhanced tumour progression, as well as progressive
fibrosis in multiple organ systems and suppression of the
immune system. Studies of animal models of pulmonary
fibrosis2e6 and lung sections from patients with idiopathic
interstitial pneumonias (IIPs)7,8 suggest an important role
for TGF-b1 in pulmonary fibrosis. This profibrotic cytokine
is secreted by most cell types as a latent, biologically inac-
tive complex that has to be activated extracellularly for re-
ceptor binding.9 Although high levels of immunoreactivity
for TGF-b1 were observed in patients with idiopathic pul-
monary fibrosis (IPF), especially in alveolar macrophages,
the autocrine or paracrine effects of TGF-b1 can therefore
only manifest themselves upon the activation of secreted
TGF-b1.7
TSP-1 is a multifunctional matricellular glycoprotein10
expressed by a variety of cell types including platelets,
macrophages, fibroblasts, vascular smooth muscle cells,
and endothelial cells. It is often found at the sites of
inflammation and wound healing.11 In addition, TSP-1 can
inhibit and stimulate angiogenesis and tumour progression,
as well as affect wound healing, platelet aggregation, and
arterial remodelling through its various domains and bind-
ing sites.12 TSP-1 expression in vitro is regulated by various
cytokines such as platelet-derived growth factor, fibroblast
growth factor-2, and TGF-b.11 TSP-1 has also been identi-
fied as a major activator of latent TGF-b in vitro and
during mouse postnatal development in vivo.13,14 The
activation of alveolar macrophage-derived latent TGF-b
in vitro requires a complex interaction of plasmin with
TSP-1 and its receptor CD36.5 This is likely to be important
in vivo for bleomycin-induced pulmonary fibrosis, where
a synthetic CD36 peptide abrogated TGF-b activation and
tissue fibrosis.5,6 Kuhn et al.15 demonstrated TSP-1 in the
extracellular matrix immediately beneath the reactive
epithelium in both organizing pneumonia and IPF, thus sug-
gesting that it might be synthesized by the regenerating
epithelium. In addition, Idell et al.16 reported that the
bronchoalveolar lavage fluid (BALF) levels of TSP in
patients with adult respiratory distress syndrome corre-
lated with the composite injury scores that were used to
quantitate the degree of lung injury. Collectively, these
findings suggest that TSP-1 thus plays a role in the devel-
opment of pulmonary alveolitis leading to fibrosis.
In this study, we measured the serum and BALF levels of
TSP-1 and examined the localization of TSP-1 in patientsTable 1 Patient characteristics
UIP NSIP
Number 22 23
Sex (male/female) 16/6 8/15
Age detection (years) 64 (34e77) 57 (
Smoking (never/ex./current) 8/10/4 16/5/
%VC (%) 80.0 (43.3e117.0) 78.1 (
%DLCO (%) 51.1 (14.2e118.5)a 62.8 (
PaO2 (Torr) 85.1 (58.3e103.3) 83.0 (
Data are the median (range). N.D.; not done.
a Compared with sarcoidosis (p< 0.01).with IPF and non-specific interstitial pneumonia (NSIP), the
two largest subsets in IIPs. The role of TSP-1 in the
pathogenesis of these diseases is discussed in the context
of our findings.Materials and methods
Study population
The study protocol was approved by the Human Ethics
Review Committees of Nagasaki University School of Med-
icine and Oita University Faculty of Medicine. Seventy-
three patients and healthy volunteers were enrolled in this
study. A signed consent form was obtained from each
subject. The subjects included 22 patients with IPF who
were pathologically diagnosed to have usual interstitial
pneumonia (UIP), 23 with idiopathic NSIP, 28 with pulmo-
nary sarcoidosis as a control disease, and 15 healthy
volunteers (Table 1). In all patients with IIPs, the diagnosis
was pathologically confirmed using surgical lung biopsy
specimens obtained from at least two different sites. The
NSIP patients included 18 fibrosing NSIP cases and 5 cellular
and fibrosing NSIP cases. None of the enrolled patients had
received either steroids or immunosuppressive therapy at
the time of clinical sample collection. Any patients with
cancer in any organ or those suspected of having a malig-
nancy were excluded from the study. Any patients with
UIP and NSIP associated with collagen vascular diseases
were also excluded. All healthy volunteers had normal
chest radiographs, were free of symptoms, and were not
taking any medications.
BAL procedure and blood sampling
After obtaining informed consent, BAL was performed as
described previously17,18 using a flexible fiberoptic bron-
choscope (Olympus P-20, Olympus, Tokyo, Japan). The
BALF was passed through BD Falcon Cell Strainers and
then centrifuged at 500 g for 10 min at 4 C. The remain-
ing fluid was centrifuged at 500 g for 5 min, and the
supernatant was stored at 80 C for further quantification
of non-cellular components including TSP-1. Peripheral
venous blood samples were obtained from all subjects on
the day of BAL sampling and the serum was stored at
80 C until analysis.Sarcoidosis Healthy volunteers
28 15
14/14 12/3
28e77) 55 (26e75) 23 (19e33)
2 16/8/4 14/0/1
33.0e135.3) 90.6 (71.5e121.6) N.D.
34.6e109.3) 80.7 (47.8e105.5) N.D.
61.4e95.2) 88.2 (64.8e95.2) N.D.
Thrombospondin-1 in interstitial pneumonia 1627Measurements of TSP-1, KL-6, SP-A, SP-D, and VEGF
We measured the levels of each marker using specific kits
according to the protocols provided by the manufacturers.
The TSP-1 levels in serum and BALF were measured by
a competitive enzyme immunoassay (EIA) using a commer-
cially available kit (CHEMICON International, Temecula,
CA). The KL-6 levels were measured using a sandwich-
type electrochemiluminescence immunoassay kit (Sanko
Junyaku Co., Tokyo). The surfactant protein A (SP-A) and
SP-D levels were measured using sandwich-type EIA kits
(Sysmex Corp., Hyogo and Yamasa Shoyu Co., Tokyo,
respectively). We also measured the serum levels of
vascular endothelial growth factor (VEGF) in each subject
using an EIA kit (Pierce, Rockford, IL) to test for angiogen-
esis. All assays were performed in duplicate.
Immunohistochemistry of lung tissues
To confirm the localization of TSP-1 in the lungs, an
immunohistochemical analysis was performed for TSP-1
(Clone A6.1, Lab Vision Corporation, CA), SP-A (Vision-
BioSystems Novocastra, UK), and CD68 (DakoCytomation,
Denmark) using paraffin-embedded sequential lung sections
obtained from five UIP cases and five NSIP cases. The
control specimens were obtained from the normal part of
the lung removed for lung cancer. Briefly, after deparaffi-
nization and rehydration, the tissue sections (4-mm thick-
ness) were soaked in 0.3% H2O2 with absolute methanol for
20 min to inactivate endogenous peroxidases. The lung
sections were incubated overnight at 4 C with primary
antibodies in a moist chamber. After washing in phosphate
buffered saline, the sections were incubated for 30 min
with EnVisionþ (Peroxidase, Mouse, DakoCytomation,
Denmark), and then developed with 3,30-diaminobenzidine
for TSP-1 and AECþ Substrate-Chromogen (DakoCytoma-
tion, Denmark) for SP-A and CD68. The primary antibody
was replaced by an irrelevant immunoglobulin G1 as a neg-
ative control. The number of SP-A positive type II pneumo-
cytes and CD68 positive alveolar macrophages that
expressed TSP-1 in the active fibrotic areas of UIP and
NSIP was counted at 400 magnification in five randomlyTable 2 BAL fluid findings and serum biomarkers
UIP NSIP
Cell differentials (%)
Macrophages 81.9 (45.8e94.0) 49.5 (21.7
Lymphocytes 10.0 (2.0e33.2) 41.6 (7.2e
Neutrophils 3.6 (0e21.6)a 1.9 (0e2
Eosinophils 2.3 (0e18.3)a 2.0 (0e1
CD4/CD8 ratio 1.4 (0.3e4.7) 0.5 (0.1e
Serum KL-6 (U/ml) 677 (444e2530) 1100 (192
Serum SP-A (ng/ml) 85.6 (25.0e118.0) 58.3 (20.3
Serum SP-D (ng/ml) 194.0 (106.0e531.0) 273.0 (17.2
Serum VEGF (pg/ml) 119.1 (23.1e592.6)a,c 254.5 (30.8
Data are the median (range). N.D.; not done.
a Compared with healthy volunteers (p< 0.01).
b Compared with UIP (p< 0.01).
c Compared with sarcoidosis (p< 0.05).selected fields in the lung specimen obtained from each
individual. The results were expressed as the median
(range) of the total number of five fields.
Statistical analysis
All values were expressed as the median (range). The
differences between groups were examined using the
ANOVA test with a post hoc analysis (Bonferroni/Dunn
test). The correlations between two variables were de-
termined using Spearman’s rank correlation analysis. A p-
value below 0.05 denoted a statistically significant
difference.Results
BALF differential cell count
The differential cell counts in BALF for the four subject
groups are listed in Table 2. In the patients with idiopathic
NSIP and pulmonary sarcoidosis, the percentages of alveo-
lar macrophages were significantly lower in comparison to
the healthy volunteers (p< 0.01), while there were more
lymphocytes in patients with NSIP and sarcoidosis in
comparison to the patients with UIP and the healthy volun-
teers (pZ 0.005, respectively). The percentages of neutro-
phils and eosinophils were significantly higher in the
patients with UIP, while the CD4/CD8 ratio was significantly
higher in the patients with sarcoidosis, in comparison to the
healthy volunteers (p< 0.01, respectively).
Serum and BALF levels of TSP-1
The serum levels of TSP-1 in the patients with UIP and NSIP
were significantly higher than those in the patients with
sarcoidosis (Fig. 1A, p< 0.0001, each) and the healthy
volunteers (p< 0.0001, each), but the levels were not signif-
icantly different between the UIP and NSIP patients. The
BALF levels of TSP-1 in the patients with UIP and NSIP were
significantly lower than in those with sarcoidosis (Fig. 1B,
p< 0.0001, each) or the healthy volunteers (p< 0.005,Sarcoidosis Healthy volunteers
e89.0)a 57.3 (7.6e86.0)a 88.1 (69.0e93.7)
69.9)a,b 39.4 (9.0e81.5)a,b 8.5 (3.4e19.9)
7.0) 0.6 (0e12.0) 0.5 (0e14.6)
5.0) 0.5 (0e5.9)b 0 (0e7.0)
2.3) 4.2 (1.1e16.7)a 0.7 (0.3e1.8)
e3570) N.D. N.D.
e253.0) N.D. N.D.
e721.0) N.D. N.D.
e636.4)a,c 63.1 (44.1e630.5)a 11.0 (0e134.2)
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Figure 1 Thrombospondin-1 (TSP-1) levels in serum (A) and
bronchoalveolar lavage fluid (BALF) (B) of patients with idio-
pathic usual interstitial pneumonia (UIP), idiopathic non-
specific interstitial pneumonia (NSIP), pulmonary sarcoidosis,
and healthy volunteers. The P-values for the overall compari-
son of all four subject groups are given.
1628 M. Ide et al.each). The TSP-1 levels in BALF were slightly lower in the
patients with UIP than in those with NSIP (p< 0.05; Fig. 1B).
Correlations between TSP-1 levels and clinical data
We examined the correlation between the serum levels of
TSP-1 and the various clinical parameters of the patients
with IIPs (UIP plus NSIP). The serum TSP-1 levels correlated
inversely with the %VC (rZ0.37, p< 0.05), but there was
no correlation between the serum TSP-1 level and the other
clinical parameters, such as the other pulmonary function
indicators, PaO2, BALF cell proportions, the well-known se-
rum markers for interstitial pneumonia (Table 2; KL-6, SP-A
and SP-D), and patient survival. There was a strong correla-
tion, however, between the serum levels of TSP-1 and VEGF
in the patients with IIPs (rZ 0.66, pZ 0.0004), which
were significantly higher than those in the control subjects
(Table 2).
Localization of TSP-1
Immunohistochemical staining for TSP-1 demonstrated high
levels of immunoreactivity predominantly in the SP-A
positive type II pneumocytes (Fig. 2aec), CD68 positivealveolar macrophages (Fig. 2eeg), and weakly in the infil-
trating mononuclear cells. There was almost no detectable
TSP-1 signal in the bronchial epithelial cells and fibroblasts.
A stronger TSP-1 signal was detected in the active fibrotic
areas in the lungs of the patients with both NSIP and UIP
(Fig. 2a,e). The number of TSP-1/SP-A double positive cells
was 312.0 (179e621) in the UIP patients and 272.5 (97e470)
in the NSIP patients (not significantly different). The num-
ber of TSP-1/CD68 double positive cells was 61.0 (35e
118) in the UIP patients and 68.5 (43e216) in the NSIP
patients (not significantly different). Minimal staining was
seen in the airway epithelium in the control lung tissue
(Fig. 2i).Discussion
The role of TSP-1 in pulmonary inflammation/fibrosis and
connective tissue synthesis has been previously demon-
strated in an experimental rat model.5,6 The activated
alveolar macrophages obtained from rat lungs after bleo-
mycin administration released increased amounts of active
TGF-b1 as well as plasmin and TSP-1. Previous reports
indicate that the activation of latent TGF-b1 by plasmin
may occur at the cell surface of the activated alveolar mac-
rophages and requires a TSP-1/CD36 (a receptor for TSP-1)
interaction.5 In turn, a decreased availability of the cell-
derived active TGF-b1 or a disruption of the TSP-1/CD36
interaction might lead to reduced inflammation and fibrosis
after bleomycin-induced lung injury.6 Azuma et al.19 also
showed a limited amount of TSP-1/2 in the platelets of con-
trol mice, but it was observed in the foamy cells of the
fibrotic lesions induced by bleomycin. These observations
implicated TSP-1 in the pathogenesis of lung injury and
fibrosis. However, the relationship between TSP-1 and the
interstitial pneumonias in humans has not yet been fully
evaluated.
The major finding of the present study is that the
patients with IIPs had elevated levels of TSP-1 in the serum
and low levels in the BALF in comparison to the sarcoidosis
patients and the healthy control patients. In addition, in
the lung sections with IIPs, TSP-1 was prominently ex-
pressed in the regenerated alveolar epithelium and alveolar
macrophages in active fibrotic lesions. This suggests that
the local production of TSP-1 by the alveolar epithelium or
alveolar macrophages is accelerated and that this elevated
production may reflect the circulating TSP-1 levels. This is
the first report of elevated TSP-1 levels in the serum of
patients with IIPs. However, this study has several limita-
tions. The study population was heterogeneous, and the
participants were at different stages of their disease. These
methodological compromises were necessary to compile
a study cohort of sufficient size. In addition, the patients
and controls were not well matched for age and this
reflects our difficulty in recruiting non-diseased elderly
controls. In addition, we did not clearly elucidate whether
age and smoking affect either the serum or BALF concen-
trations of TSP-1. Furthermore, careful interpretation
should be applied to such findings regarding TSP-1, because
the serum levels of TSP-1 correlate with the cancer stage in
certain cancer types20e22 including non-small-cell lung can-
cer,23 while also increasing in patients with other diseases
Figure 2 Photomicrographs of immunohistochemical stain of TSP-1, surfactant protein A (SP-A), and CD68 in sequential lung sec-
tions of NSIP (aed), UIP (eeh), and normal lung (i). Note the positive TSP-1 staining (brown; a, b, e, f) in the SP-A positive type II
pneumocytes (red; c) and CD68 positive alveolar macrophages (red; g). No staining with isotype control (d, h). The TSP-1 signal in
normal lung was quite low (i). Magnification; 40 (a, e, i), 200 (b, c, d), 100 (f, g, h).
Thrombospondin-1 in interstitial pneumonia 1629such as systemic sclerosis24 and dermatomyositis.25 In this
study, the elevated levels of TSP-1 in the patients with
IIPs correlated significantly with those of an angiogenic cy-
tokine VEGF. TSP-1 is also known to affect angiogenesis.
Simler et al.26 showed that the circulating levels of other
angiogenic cytokines, such as VEGF, endothelin-1 (ET-1),
and interleukin-8 were high and were significantly related
to the HRCT fibrosis score in the patients with IIPs. In our
study, although the plasma ET-1 levels [3.48 (2.78e4.46)
pg/ml in the UIP patients, 3.32 (2.68e4.54) pg/ml in the
NSIP patients] did not correlate with the serum or BALF
levels of TSP-1 in the patients with IIPs (data not shown),
our data suggest that TSP-1 might thus play a similar role
to VEGF-related angiogenesis in interstitial pneumonia.
Similar to previous findings for the BALF levels of SP-A in
IIP patients,18,27 the present study showed lower levels of
TSP-1 in the BALF, even in the presence of high serum levels
in the patients with IIPs. This could reflect reduced access
to the alveolar compartment, reduced production of TSP-1
by the damaged alveolar epithelium, or an increased up-
take and degradation by alveolar macrophages and airway
epithelial cells. In addition, Yehualaeshet et al.5 reported
an increased TSP-1 secretion from explanted rat alveolar
macrophages that reached maximal levels 7 days after
bleomycin administration, declining rapidly thereafter to
the control levels of alveolar macrophages from normalrats. This suggests the possibility of relatively low levels
of TSP-1 in the lung alveoli of patients in the chronic phase
of IIPs. However, the exact mechanism underlying this
clearance of TSP-1 remains unclear, and we could not
clarify this point in this study.
Pulmonary fibrosis remains a devastating clinical disor-
der for which there are limited therapeutic options. The
pathogenesis of IPF also remains largely unknown, but
observations based on the animal models of the pulmonary
fibrosis2e6 and lung tissue specimens from patients with
IPF7,8 suggest that TGF-b plays a key role in pulmonary
inflammation/fibrosis. TSP-1 was identified as a major acti-
vator of TGF-b in pulmonary fibrosis models in vivo.5 The
contribution of other TGF-b activators cannot be excluded,
however, the specific and localized inhibition of TGF-b
activation by TSP-1 blocking is thus considered to provide
a potential anti-TGF-b strategy for the treatment of inflam-
matory/fibrotic diseases.28 In particular, targeting TSP-1-
mediated activation of TGF-b as a therapeutic intervention
for fibrotic lung diseases could be a promising alternative
because the TGF-b protein expression and alternate activa-
tion pathways of TGF-b are not affected. In addition, the
therapeutic long-term strategies focusing on the non-
specific and systemic blockade of TGF-b ligand receptor
interactions is considered problematic due to the complex
functions of TGF-b.
1630 M. Ide et al.In summary, we herein demonstrated the presence of
high serum levels of TSP-1 in patients with IIPs in compar-
ison to the control patients, and the expression of TSP-1 in
the alveolar epithelium and macrophages in active fibrotic
lesions. The serum levels of TSP-1 did not closely correlate
with the clinical biomarkers or patient survival apart from
the %VC and the serum levels of VEGF. Our findings suggest
an association between the serum TSP-1 levels and the
presence of interstitial fibrosis, however, further studies
are required to prove a link between an increased pro-
duction of TSP-1 and the pathogenesis of the pulmonary
fibrotic responses seen in IIPs, and to elucidate the
potential of TSP-1 as a molecular target for therapeutic
intervention in the treatment of fibrotic lung diseases.
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